Blog: Patient Insights & Thought Leadership

Healthcare Industry Thought Leadership

Health Union’s data-driven industry conversations help pharma make smarter, more effective decisions.
Check out our latest thought leadership pieces below.

Patient and Caregiver Perspectives: How Pharma Can Improve the Chronic Condition Experience

November 30, 2022

Two health leaders share wins, challenges and opportunities they've faced as patient and caregiver to help pharma improve the chronic condition experience.

Understanding Rare Conditions: Support & Connection

November 8, 2022

The internet has allowed people living with chronic conditions to find information, connection and support that might not have been readily available.

Socially Driven Insights Illuminate Real-Time Patient Needs

November 7, 2022

Survey data like Health Union's "In America" socially driven insights add more context and recency for understanding patient needs in real, actionable ways.

Understanding Rare Conditions: The Quest for Reliable Information

September 28, 2022

One-third of NMOSD In America respondents said they struggle to find reliable information on neuromyelitis optica spectrum disorder.

People are concerned about returning back to normal during COVID-19.

People with Chronic Conditions Concerned About “Returning to Normal” During Pandemic

June 3, 2020

Although frustrated by COVID-19’s physical and mental toll, people with chronic conditions approach the idea of “returning to normal” with concern.

Asthma Patient-Reported Survey Data | 2020

June 3, 2020

40% of people with asthma experience symptoms at least once a day, according to Health Union survey data from its online health community.

Endometriosis Patient-Reported Survey Data | 2020

May 29, 2020

Only 13% of endometriosis patients feel controlled on their current treatment plan, according to Health Union survey data from its online health community.

Living with Myeloproliferative Neoplasms Differs from Other Forms of Blood Cancer

May 26, 2020

Health Union survey shows that, when compared to the more common forms of blood cancer, respondents living with myeloproliferative neoplasms (MPN) appear to have less traditional and, at times, more difficult treatment journeys.

Healthcare Industry Thought Leadership

Contact